CAJ | 학술논문

基于肠促胰岛素的药物包括胰高血糖素样肽-1(glucagon-like peptide-1, GLP-1)受体激动剂和二肽基肽酶-4抑制剂,目前已获准用于治疗2型糖尿病,而其未来的发展方向可能主要在于如何优化自身特点和扩展临床适应证,具体包括延长GLP-1受体激动剂的有效作用时间、开发能口服的GLP-1受体激动剂、寻找可促进GLP-1分泌的新靶点、开发其他胃肠-胰腺生物活性肽类新药以及探求此类药物在1型糖尿病、肥胖症、心血管疾病和神经退行性疾病治疗领域中的临床应用前景等.
기우장촉이도소적약물포괄이고혈당소양태-1(glucagon-like peptide-1, GLP-1)수체격동제화이태기태매-4억제제,목전이획준용우치료2형당뇨병,이기미래적발전방향가능주요재우여하우화자신특점화확전림상괄응증,구체포괄연장GLP-1수체격동제적유효작용시간、개발능구복적GLP-1수체격동제、심조가촉진GLP-1분비적신파점、개발기타위장-이선생물활성태류신약이급탐구차류약물재1형당뇨병、비반증、심혈관질병화신경퇴행성질병치료영역중적림상응용전경등.
@@@@Incretin-based drugs include glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 inhibitors, which are permitted to be used for treating the type 2 diabetes at present and their future development mainly focuses on the optimization and expand their clinical indications, including prolonging the effective duration, manufacturing oral agents and searching for the new target to stimulate the secretion of GLP-1 receptor agonists. Other gastrointestinal-pancreas bioactive peptide type drugs will be developed and their prospects of clinical application in treatment of type 1 diabetes, obesity, cardiovascular and neurodegenerative diseases are explored.